Header Logo

CHRISTOPHER G WOOD

TitleProfessor
InstitutionMD Anderson
DepartmentUrology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Borges Dos Reis R, Shu X, Ye Y, Borregales L, Karam JA, Adibi M, Wu X, Reis LO, Wood CG. Urinary miRNAs Predict Metastasis in Patients With Clinically Localized Clear Cell Renal Cell Carcinoma Treated With Nephrectomy. Clin Genitourin Cancer. 2024 02; 22(1):e156-e162.e4. PMID: 37945405.
      Citations:    Fields:    Translation:Humans
    2. Esdaille AR, Karam JA, Master VA, Spiess PE, Raman JD, Sharma P, Shapiro DD, Das A, Sexton WJ, Zemp L, Patil D, Allen GO, Matin SF, Wood CG, Abel EJ. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology. 2023 12; 182:168-174. PMID: 37690543.
      Citations:    Fields:    Translation:Humans
    3. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684. PMID: 37164948; PMCID: PMC10172300.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    4. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 09; 9(5):734-741. PMID: 36863962; PMCID: PMC10460829.
      Citations: 1     Fields:    
    5. Moore JA, Lehner MJ, Anfossi S, Datar S, Tidwell RS, Campbell M, Shah AY, Ward JF, Karam JA, Wood CG, Pisters LL, Calin GA, Tu SM. Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass. 2023 Jan; 4(1):81-87. PMID: 36569509; PMCID: PMC9766861.
      Citations:    
    6. Pollard AC, Paolillo V, Radaram B, Qureshy S, Li L, Maity T, Wang L, Uddin MN, Wood CG, Karam JA, Pagel MD, Piwnica-Worms D, Millward SW, Fowlkes NW, Norton W, Engel BJ, Pisaneschi F, Zacharias NM. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine. Mol Imaging Biol. 2022 12; 24(6):959-972. PMID: 35732988; PMCID: PMC9681699.
      Citations:    Fields:    
    7. Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246. PMID: 35092681; PMCID: PMC9016449.
      Citations:    Fields:    Translation:Humans
    8. Moore JA, Slack RS, Lehner MJ, Campbell MT, Shah AY, Zhang M, Guo CC, Ward JF, Karam JA, Wood CG, Pisters LL, Tu SM. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel). 2022 Feb 23; 14(5). PMID: 35267435; PMCID: PMC8909729.
      Citations:    
    9. Westerman ME, Yevich SM, Dori Y, Ward JF, Pisters LL, Karam JA, Wood CG, Avritscher R, Matin SF. Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urological surgery. BJU Int. 2022 05; 129(5):585-587. PMID: 34962705.
      Citations:    Fields:    Translation:Humans
    10. Tsai CW, Chang WS, Xu Y, Huang M, Tamboli P, Wood CG, Bau DT, Gu J. Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients. Am J Cancer Res. 2022; 12(2):852-860. PMID: 35261807; PMCID: PMC8899987.
      Citations:    
    11. Falahkheirkhah K, Guo T, Hwang M, Tamboli P, Wood CG, Karam JA, Sircar K, Bhargava R. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Lab Invest. 2022 05; 102(5):554-559. PMID: 34963688; PMCID: PMC9050807.
      Citations:    Fields:    Translation:Humans
    12. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel). 2021 Nov 30; 13(23). PMID: 34885132; PMCID: PMC8656882.
      Citations: 2     
    13. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375. PMID: 34737281; PMCID: PMC8569213.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    14. Karam JA, Puligandla M, Flaherty KT, Uzzo RG, Matin SF, Pins MR, Wood CG, Kane C, Jewett MAS, Kim SE, Dutcher JP, DiPaola RS, Haas NB. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805. BJU Int. 2022 06; 129(6):718-722. PMID: 34480522; PMCID: PMC9423939.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    15. Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol. 2021 12; 39(12):837.e9-837.e17. PMID: 34551888; PMCID: PMC9486901.
      Citations: 1     Fields:    Translation:Humans
    16. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408. PMID: 34625389.
      Citations: 1     Fields:    Translation:Humans
    17. Tu SM, Zhang M, Wood CG, Pisters LL. Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers (Basel). 2021 Aug 09; 13(16). PMID: 34439162; PMCID: PMC8394880.
      Citations: 4     
    18. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620. PMID: 34228889; PMCID: PMC10097479.
      Citations: 1     Fields:    Translation:Humans
    19. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23. PMID: 34301458.
      Citations:    Fields:    Translation:Humans
    20. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Correction: Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2021 Jun 01; 27(11):3265. PMID: 34074655.
      Citations:    Fields:    
    21. Pisters PW, Ranasinghe W, Wei W, Wood CG, Matin SF, Ward JF, Pisters LL. Long-term renal functional outcomes following ureteroureterostomy performed during multi-organ resection for non-urothelial cancers. BJUI Compass. 2021 Sep; 2(5):348-354. PMID: 35474874; PMCID: PMC8988638.
      Citations: 2     
    22. McIntosh AG, Umbreit EC, Wood CG, Matin SF, Karam JA. Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Transl Androl Urol. 2021 May; 10(5):2233-2245. PMID: 34159106; PMCID: PMC8185683.
      Citations:    
    23. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9). PMID: 33946504; PMCID: PMC8124338.
      Citations: 2     
    24. Abdelsalam ME, Sabir SH, Ba SBK, Karam JA, Matin SF, Wood CG, Ahrar K. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. AJR Am J Roentgenol. 2021 07; 217(1):157-163. PMID: 33909469.
      Citations:    Fields:    Translation:Humans
    25. Zacharias NM, Wang L, Maity T, Li L, Millward SW, Karam JA, Wood CG, Navai N. Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. Int J Mol Sci. 2021 Mar 11; 22(6). PMID: 33799686; PMCID: PMC8001211.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    26. Shaw LK, Wiele AJ, Sircar K, Wood CG, Msaouel P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treat Res Commun. 2021; 27:100349. PMID: 33725559; PMCID: PMC8127401.
      Citations:    Fields:    Translation:Humans
    27. Correa AF, Jegede OA, Haas NB, Flaherty KT, Pins MR, Adeniran A, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. Eur Urol. 2021 07; 80(1):20-31. PMID: 33707112; PMCID: PMC8627688.
      Citations: 3     Fields:    Translation:Humans
    28. Choueiri TK, Atkins MB, Bakouny Z, Carlo MI, Drake CG, Jonasch E, Kapur P, Lewis B, Linehan WM, Mitchell MJ, Pal SK, Pels K, Poteat S, Rathmell WK, Rini BI, Signoretti S, Tannir N, Uzzo R, Wood CG, Hammers HJ. Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. J Natl Cancer Inst. 2021 03 01; 113(3):234-243. PMID: 32359162; PMCID: PMC7936057.
      Citations: 6     Fields:    Translation:HumansAnimals
    29. Umbreit EC, McIntosh AG, Suk-Ouichai C, Karam JA, Wood CG. The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian J Urol. 2021 Jan-Mar; 37(1):13-19. PMID: 33850351; PMCID: PMC8033221.
      Citations:    
    30. Umbreit EC, Siddiqui BA, Hwang MJ, Joon AY, Maity T, Westerman ME, Merriman KW, Alhasson H, Uthup J, Guo T, Moore JA, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang M, Tu SM. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020 Dec 14; 12(12). PMID: 33327406; PMCID: PMC7764868.
      Citations: 8     
    31. Wood CG, Ferguson JE, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, Rathmell WK. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight. 2020 11 19; 5(22). PMID: 33208553; PMCID: PMC7710285.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    32. Rini B, Abel EJ, Albiges L, Bex A, Brugarolas J, Bukowski RM, Coleman JA, Drake CG, Figlin RA, Futreal A, Hammers H, Powles T, Rathmell WK, Ricketts CJ, Turajlic S, Wood CG, Leibovich BC. Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. Clin Genitourin Cancer. 2021 04; 19(2):167-175. PMID: 33358149.
      Citations: 1     Fields:    Translation:Humans
    33. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16. PMID: 33187886.
      Citations: 1     Fields:    Translation:Humans
    34. Umbreit EC, McIntosh AG, Suk-Ouichai C, Segarra LA, Holland LC, Fellman BM, Williams SB, Thomas AZ, Tu SM, Pettaway CA, Pisters LL, Ward JF, Wood CG, Karam JA. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer. 2020 11 15; 126(22):4878-4885. PMID: 32940929; PMCID: PMC9379780.
      Citations: 1     Fields:    Translation:Humans
    35. Shapiro DD, Westerman ME, Karam JA, Wood CG. Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question? Cancer J. 2020 Sep/Oct; 26(5):382-389. PMID: 32947306.
      Citations:    Fields:    Translation:Humans
    36. Westerman ME, Shapiro DD, Tannir NM, Campbell MT, Matin SF, Karam JA, Wood CG. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020 12; 126(6):745-753. PMID: 32623821.
      Citations: 3     Fields:    Translation:Humans
    37. Westerman ME, Wood CG. Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Ann Transl Med. 2020 Aug; 8(16):1037. PMID: 32953837; PMCID: PMC7475466.
      Citations: 1     
    38. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982. PMID: 32586940; PMCID: PMC7968518.
      Citations: 9     Fields:    Translation:HumansCells
    39. Westerman ME, Shapiro DD, Wood CG, Karam JA. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. Urol Clin North Am. 2020 Aug; 47(3):329-343. PMID: 32600535.
      Citations:    Fields:    Translation:Humans
    40. McIntosh AG, Umbreit EC, Holland LC, Gu C, Tannir NM, Matin SF, Karam JA, Culp SH, Wood CG. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020 09 01; 126(17):3950-3960. PMID: 32515845.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    41. Msaouel P, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Karki M, Seervai RNH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM, Malouf GG, Pili? PG, Vokshi BH, Davidson I. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13. PMID: 32359397; PMCID: PMC7288373.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    42. Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, Kapoor A, Vaena D, Lowrance W, Bratslavsky G, DeBenedette M, Gamble A, Plachco A, Norris MS, Horvatinovich J, Tcherepanova IY, Nicolette CA, Wood CG, ADAPT study group. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 05 15; 26(10):2327-2336. PMID: 32034074.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    43. Shapiro DD, Karam JA, Wood CG. EDITORIAL COMMENT. Urology. 2020 02; 136:175. PMID: 32033671.
      Citations:    Fields:    Translation:Humans
    44. Grant SR, Lei X, Hess KR, Smith GL, Matin SF, Wood CG, Nguyen Q, Frank SJ, Anscher MS, Smith BD, Karam JA, Tang C. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Adv Radiat Oncol. 2020 May-Jun; 5(3):495-502. PMID: 32529146; PMCID: PMC7276675.
      Citations: 2     
    45. Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 12 20; 7(1):354. PMID: 31856918; PMCID: PMC6924043.
      Citations: 63     Fields:    Translation:Humans
    46. Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, Shariat SF, Hsieh JT, Wu WJ. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 2020 05; 38(5):496-505. PMID: 31862213.
      Citations: 2     Fields:    Translation:Humans
    47. Borregales LD, Adibi M, Thomas AZ, Reis RB, Chery LJ, Devine CE, Wang X, Potretzke AM, Potretzke T, Figenshau RS, Bauman TM, Aboshady YI, Abel EJ, Matin SF, Karam JA, Wood CG. Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. Eur Urol Focus. 2021 03; 7(2):397-403. PMID: 31685445.
      Citations: 4     Fields:    Translation:Humans
    48. Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2020 04; 203(4):684-689. PMID: 31596672; PMCID: PMC7337326.
      Citations: 5     Fields:    Translation:Humans
    49. Zacharias NM, Baran N, Shanmugavelandy SS, Lee J, Lujan JV, Dutta P, Millward SW, Cai T, Wood CG, Piwnica-Worms D, Konopleva M, Bhattacharya PK. Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. Mol Cancer Ther. 2019 11; 18(11):1937-1946. PMID: 31387889; PMCID: PMC7080291.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    50. Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2020 10; 3(5):687-694. PMID: 31272939; PMCID: PMC6938577.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    51. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707. PMID: 31231128.
      Citations: 10     Fields:    Translation:HumansCells
    52. Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. J Clin Oncol. 2019 08 10; 37(23):2062-2071. PMID: 31216227; PMCID: PMC7085167.
      Citations: 20     Fields:    Translation:Humans
    53. Zacharias NM, Ornelas A, Lee J, Hu J, Davis JS, Uddin N, Pudakalakatti S, Menter DG, Karam JA, Wood CG, Hawk ET, Kopetz S, Vilar E, Bhattacharya PK, Millward SW. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. 2019 03 22; 58(13):4179-4183. PMID: 30680862; PMCID: PMC6467058.
      Citations: 4     Fields:    Translation:AnimalsCells
    54. Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019 Nov; 37(11):2419-2427. PMID: 30759271.
      Citations: 2     Fields:    Translation:Humans
    55. Yu KJ, Keskin SK, Meissner MA, Petros FG, Wang X, Borregales LD, Gu C, Tamboli P, Matin SF, Wood CG, Karam JA. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer. 2018 10 15; 124(20):4023-4031. PMID: 30276798.
      Citations: 10     Fields:    Translation:Humans
    56. Capitanio U, Staehler M, Wood CG, Leibovich BC, Van Poppel H, Bensalah K, Young Academic Urologists Kidney Cancer Working Group of the European Association of Urology, Ouzaid I, Ljungberg B. Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. Eur Urol Oncol. 2019 03; 2(2):141-149. PMID: 31017089.
      Citations: 18     Fields:    Translation:Humans
    57. Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN, Wu X. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496. PMID: 30201497; PMCID: PMC6207099.
      Citations: 16     Fields:    Translation:Humans
    58. Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020 01 15; 6(1):104-111. PMID: 30206003; PMCID: PMC7771285.
      Citations: 6     Fields:    Translation:HumansCells
    59. Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, Wood CG, Matin SF. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2019 03; 123(3):447-455. PMID: 30007044.
      Citations: 2     Fields:    Translation:Humans
    60. Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C, Roman-Gonzalez A. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg. 2018 07; 268(1):172-178. PMID: 28257320.
      Citations: 23     Fields:    Translation:Humans
    61. Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757. PMID: 29635281; PMCID: PMC5972595.
      Citations: 8     Fields:    Translation:Humans
    62. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034. PMID: 29804202; PMCID: PMC6261784.
      Citations: 1     Fields:    Translation:Humans
    63. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol. 2018 Jul; 36(7):343.e1-343.e8. PMID: 29748098.
      Citations: 2     Fields:    Translation:Humans
    64. Meissner MA, McCormick BZ, Karam JA, Wood CG. Adjuvant therapy for advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2018 07; 18(7):663-671. PMID: 29707987.
      Citations: 6     Fields:    Translation:Humans
    65. Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology. 2018 Jun; 116:114-119. PMID: 29578041.
      Citations: 7     Fields:    Translation:Humans
    66. Petros FG, Metcalfe MJ, Yu KJ, Keskin SK, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World J Urol. 2018 Jul; 36(7):1093-1101. PMID: 29488096.
      Citations: 9     Fields:    Translation:Humans
    67. McCormick B, Meissner MA, Karam JA, Wood CG. Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2017 Nov 27; 1(2):115-121. PMID: 30334013; PMCID: PMC6179118.
      Citations:    
    68. Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL. BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia. 2018 01; 20(1):32-43. PMID: 29190493; PMCID: PMC5711998.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    69. Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X. Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma. Carcinogenesis. 2017 10 26; 38(11):1129-1135. PMID: 28968893; PMCID: PMC5862287.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    70. Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer. 2018 04; 16(2):e443-e450. PMID: 29113770; PMCID: PMC7771342.
      Citations: 3     Fields:    Translation:Humans
    71. Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Raman JD, Wood CG, Margulis V, Briganti A, Montorsi F, Shariat SF, European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Cancer Group and the, Dobruch J, Roupret M, Xylinas E. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the?Upper Tract Urothelial Carcinoma Collaboration. BJU Int. 2018 02; 121(2):252-259. PMID: 28940605.
      Citations: 25     Fields:    Translation:Humans
    72. Xiao ZD, Han L, Lee H, Zhuang L, Zhang Y, Baddour J, Nagrath D, Wood CG, Gu J, Wu X, Liang H, Gan B. Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nat Commun. 2017 10 04; 8(1):783. PMID: 28978906; PMCID: PMC5627275.
      Citations: 94     Fields:    Translation:HumansCells
    73. Karam JA, Wood CG. Editorial Comment. J Urol. 2018 01; 199(1):52. PMID: 28945990.
      Citations:    Fields:    Translation:Humans
    74. Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, Matin SF, Wood CG, Karam JA. Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. J Urol. 2018 02; 199(2):393-400. PMID: 28941919.
      Citations: 10     Fields:    Translation:Humans
    75. Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831. PMID: 28832979; PMCID: PMC5731248.
      Citations: 36     Fields:    Translation:HumansCells
    76. Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953. PMID: 28731777; PMCID: PMC5915259.
      Citations: 9     Fields:    Translation:Humans
    77. Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol. 2018 01; 199(1):53-59. PMID: 28728992; PMCID: PMC5800986.
      Citations: 13     Fields:    Translation:Humans
    78. Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. J Urol. 2017 12; 198(6):1269-1277. PMID: 28709887.
      Citations: 2     Fields:    Translation:Humans
    79. Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA, Ch?ry L. The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology. 2017 10; 108:114-121. PMID: 28705573; PMCID: PMC5790178.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    80. Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017 07; 13(7):414-421. PMID: 28697319; PMCID: PMC5508447.
      Citations: 18     Fields:    Translation:Humans
    81. Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V, Xylinas E. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2017 12; 198(6):1253-1262. PMID: 28668287.
      Citations: 25     Fields:    Translation:Humans
    82. Shu X, Purdue MP, Ye Y, Tu H, Wood CG, Tannir NM, Wang Z, Albanes D, Gapstur SM, Stevens VL, Rothman N, Chanock SJ, Wu X. Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes. Cancer Epidemiol Biomarkers Prev. 2017 09; 26(9):1436-1442. PMID: 28626070; PMCID: PMC5581698.
      Citations: 1     Fields:    Translation:Humans
    83. Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X, Mendoza-P?rez J. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627. PMID: 28543182; PMCID: PMC5589484.
      Citations: 13     Fields:    Translation:HumansCells
    84. Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, Lorentz CA, Bloom E, Bauman TM, Wood CG, Blute ML. Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol. 2017 10; 198(4):810-816. PMID: 28411071.
      Citations: 4     Fields:    Translation:Humans
    85. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537. PMID: 28411072; PMCID: PMC5597336.
      Citations: 20     Fields:    Translation:Humans
    86. Rao P, Matrana MR, Cauley DH, Wood CG, Patel S, Tannir NM, Teegavarapu PS. Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience. Am J Clin Oncol. 2017 Apr; 40(2):189-193. PMID: 25222071; PMCID: PMC4372498.
      Citations: 5     Fields:    Translation:Humans
    87. Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 08; 198(2):281-288. PMID: 28268170.
      Citations: 13     Fields:    Translation:Humans
    88. Leal I, Milbury K, Engebretson J, Matin S, Jonasch E, Tannir N, Wood CG, Cohen L. Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliat Support Care. 2018 04; 16(2):146-154. PMID: 28262086; PMCID: PMC5587362.
      Citations: 2     Fields:    Translation:Humans
    89. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370. PMID: 28216278.
      Citations: 8     Fields:    Translation:Humans
    90. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143; PMCID: PMC5349913.
      Citations: 14     Fields:    Translation:Humans
    91. Shah AY, Karam JA, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM, Malouf GG. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792. PMID: 27860149; PMCID: PMC6857178.
      Citations: 22     Fields:    Translation:Humans
    92. Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016; 4:81. PMID: 27891227; PMCID: PMC5109802.
      Citations: 20     Fields:    Translation:Humans
    93. Abufaraj M, Moschini M, Soria F, Gust K, Mathieu R, Margulis V, Karam JA, Wood CG, Briganti A, Bensalah K, Haitel A, Shariat SF, ?zsoy M, Roupr?t M. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017 Jul; 35(7):1073-1080. PMID: 27830374; PMCID: PMC5486535.
      Citations: 6     Fields:    Translation:Humans
    94. Kawakami F, Rao P, Tamboli P, Wood CG, Karam JA. Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial. J Urol. 2017 03; 197(3 Pt 1):559-565. PMID: 27678298.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    95. Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Kassouf W, Margulis V, Bensalah K. Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2017 03; 197(3 Pt 1):580-589. PMID: 27670916.
      Citations: 12     Fields:    Translation:Humans
    96. Chery LJ, Karam JA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2016 Sep; 14(9):696-703. PMID: 27673288.
      Citations: 1     Fields:    Translation:Humans
    97. Haitel A, Karam JA, Wood CG, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Soria F, Moschini M, Wirth GJ, Roupr?t M, ?zsoy M, Remzi M, Gust KM, Shariat SF. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World J Urol. 2017 Feb; 35(2):251-259. PMID: 27272502.
      Citations: 9     Fields:    Translation:Humans
    98. Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Karam JA, Tamboli P, Wood CG, Jelinek J, Tannir NM, Malouf GG, Raynal NJ, Allanick F, Mouawad R, Spano JP, Khayat D. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016 Dec 15; 22(24):6236-6246. PMID: 27256309; PMCID: PMC5135666.
      Citations: 22     Fields:    Translation:HumansCells
    99. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Lucca I, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, Briganti A, Shariat SF, Roupr?t M, Mbeutcha A, Xylinas E. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol. 2017 Jan; 35(1):121-130. PMID: 27209168; PMCID: PMC5233730.
      Citations: 11     Fields:    Translation:HumansCells
    100. Haitel A, Margulis V, Karam JA, Karakiewicz PI, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, Lotan Y, Bachmann A, Rink M, Briganti A, Favaretto RL, Bahadori A, Mathieu R, Grubm?ller B, Roupr?t M, Seitz C, Cunha IW, Zequi SC, Remzi M, Shariat SF. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017 Jan; 35(1):113-120. PMID: 27129576; PMCID: PMC5233747.
      Citations: 8     Fields:    Translation:Humans
    101. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84. PMID: 27036304; PMCID: PMC5014677.
      Citations: 12     Fields:    Translation:Humans
    102. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785; PMCID: PMC5071733.
      Citations: 17     Fields:    Translation:HumansCells
    103. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16. PMID: 26969090; PMCID: PMC4878938.
      Citations: 182     Fields:    Translation:HumansCTClinical Trials
    104. Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA, Malouf GG, Khayat D. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57. PMID: 26895810.
      Citations: 51     Fields:    Translation:Humans
    105. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26. PMID: 26707613; PMCID: PMC4835261.
      Citations: 4     Fields:    Translation:Humans
    106. Margulis V, Karam JA, Wood CG, Haitel A, Xylinas E, Kluth L, Karakiewicz PI, Rink M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Remzi M, Mbeutcha A, Lucca I, de Martino M, Mathieu R, Roupr?t M, Briganti A, Rieken M, Seitz C, Shariat SF, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World J Urol. 2016 Aug; 34(8):1155-61. PMID: 26658888.
      Citations: 4     Fields:    Translation:Humans
    107. Gu J, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X, Mendoza-P?rez J, Herrera LA. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82. PMID: 26655847; PMCID: PMC4834236.
      Citations: 12     Fields:    Translation:HumansCells
    108. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74. PMID: 26626617; PMCID: PMC4879109.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    109. Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016 Apr; 8(2):130-41. PMID: 27034725; PMCID: PMC4772353.
      Citations: 26     
    110. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15. PMID: 26551148; PMCID: PMC5016565.
      Citations: 13     Fields:    Translation:Humans
    111. Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol. 2015 Dec; 33(12):528-37. PMID: 26546481.
      Citations: 9     Fields:    Translation:Humans
    112. Abel EJ, Margulis V, Bauman TM, Karam JA, Christensen WP, Krabbe LM, Haddad A, Golla V, Wood CG. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU Int. 2016 Jun; 117(6B):E87-94. PMID: 26305276.
      Citations: 14     Fields:    Translation:Humans
    113. Adibi M, Kenney PA, Thomas AZ, Borregales LD, Wang X, Devine CE, Karam JA, Wood CG, Nogueras-Gonz?lez GM. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. Eur Urol. 2016 Feb; 69(2):352-60. PMID: 26382085.
      Citations: 4     Fields:    Translation:Humans
    114. Thomas AZ, Adibi M, Borregales LD, Wood CG, Karam JA. Role of metastasectomy in metastatic renal cell carcinoma. Curr Opin Urol. 2015 Sep; 25(5):381-9. PMID: 26125508.
      Citations: 6     Fields:    Translation:Humans
    115. Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ, Ozsari L, Hofmann MC, Zheng S, Verhaak R, Pagliaro L, Cortez MA, Lee MH, Yeung SC, Habra MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res. 2015 Oct 01; 75(19):4131-42. PMID: 26282167; PMCID: PMC4592476.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    116. Mathieu R, Klatte T, Margulis V, Karam JA, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Rink M, Kluth LA, Scherr DS, Robinson BD, Shariat SF, Roupr?t M. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2015 Nov; 33(11):495.e15-22. PMID: 26228160.
      Citations: 7     Fields:    Translation:Humans
    117. Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24. PMID: 27499906; PMCID: PMC4939892.
      Citations: 5     Fields:    
    118. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5. PMID: 26032863; PMCID: PMC4666814.
      Citations: 26     Fields:    Translation:Humans
    119. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, Wood CG, Karam JA. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int. 2016 May; 117(5):775-82. PMID: 26053895; PMCID: PMC4670601.
      Citations: 21     Fields:    Translation:Humans
    120. Karam JA, Devine CE, Fellman BM, Urbauer DL, Abel EJ, Allaf ME, Bex A, Lane BR, Thompson RH, Wood CG. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial. BJU Int. 2016 Apr; 117(4):629-35. PMID: 26033220; PMCID: PMC4666818.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    121. Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35. PMID: 26111976; PMCID: PMC4556533.
      Citations: 12     Fields:    Translation:HumansCells
    122. Thomas AZ, Adibi M, Borregales LD, Karam JA, Wood CG. Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol. 2015 Jun; 4(3):301-9. PMID: 26815334; PMCID: PMC4708236.
      Citations: 2     
    123. Haddad AQ, Leibovich BC, Abel EJ, Luo JH, Krabbe LM, Thompson RH, Heckman JE, Merrill MM, Gayed BA, Sagalowsky AI, Boorjian SA, Wood CG, Margulis V. Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. Urol Oncol. 2015 Sep; 33(9):388.e1-9. PMID: 26004163.
      Citations: 11     Fields:    Translation:HumansCells
    124. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23. PMID: 26004164; PMCID: PMC4584175.
      Citations: 14     Fields:    Translation:Humans
    125. Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res. 2015 Sep 15; 21(18):4048-54. PMID: 25967143; PMCID: PMC4573791.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    126. Youssef RF, Krabbe LM, Shariat SF, Lotan Y, Sagalowsky AI, Raman J, Wood CG, Weizer A, Roscigno M, Montorsi F, Bolenz C, Remzi M, Kassouf W, Margulis V, Bensalah K. TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. World J Urol. 2015 Dec; 33(12):1965-72. PMID: 25957592.
      Citations: 5     Fields:    Translation:Humans
    127. Klatte T, Ficarra V, Gratzke C, Kaouk J, Kutikov A, Macchi V, Mottrie A, Porpiglia F, Porter J, Rogers CG, Russo P, Thompson RH, Uzzo RG, Wood CG, Gill IS. A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. Eur Urol. 2015 Dec; 68(6):980-92. PMID: 25911061; PMCID: PMC4994971.
      Citations: 52     Fields:    Translation:Humans
    128. Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, Karam JA. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015 Jul; 116(1):85-92. PMID: 25395040.
      Citations: 20     Fields:    Translation:Humans
    129. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22. PMID: 25758610; PMCID: PMC4666307.
      Citations: 13     Fields:    Translation:Humans
    130. Shu X, Purdue MP, Ye Y, Wood CG, Chen M, Wang Z, Albanes D, Pu X, Huang M, Stevens VL, Diver WR, Gapstur SM, Virtamo J, Chow WH, Tannir NM, Dinney CP, Rothman N, Chanock SJ, Wu X. Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget. 2015 Feb 28; 6(6):4097-109. PMID: 25784652; PMCID: PMC4414175.
      Citations:    Fields:    Translation:Humans
    131. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9. PMID: 25700975; PMCID: PMC4664068.
      Citations: 20     Fields:    Translation:Humans
    132. Karam JA, Babaian KN, Tannir NM, Matin SF, Wood CG. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol. 2015 Jun; 67(2):149-56. PMID: 25645343.
      Citations:    Fields:    Translation:Humans
    133. Karam JA, Wood CG, Compton ZR, Rao P, Vikram R, Ahrar K, Matin SF. Salvage surgery after energy ablation for renal masses. BJU Int. 2015 Jan; 115(1):74-80. PMID: 24656119.
      Citations: 7     Fields:    Translation:Humans
    134. Melkonian SC, Wang X, Gu J, Matin SF, Tannir NM, Wood CG, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma. Carcinogenesis. 2015 Feb; 36(2):249-55. PMID: 25524925; PMCID: PMC4322190.
      Citations: 12     Fields:    Translation:HumansCells
    135. Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. J Urol. 2015 May; 193(5):1486-93. PMID: 25451830.
      Citations: 15     Fields:    Translation:Humans
    136. Adibi M, Karam JA, Wood CG. Reporting geographic and temporal trends in renal cell carcinoma: why is this important? Eur Urol. 2015 Mar; 67(3):531-2. PMID: 25454608.
      Citations: 3     Fields:    Translation:Humans
    137. Babaian KN, Kim DY, Kenney PA, Wood CG, Wong J, Sanchez C, Fang JE, Gerber JA, Didic A, Wahab A, Golla V, Torres C, Tamboli P, Qiao W, Matin SF, Wood CG, Karam JA. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol. 2015 Apr; 193(4):1101-7. PMID: 25390078.
      Citations: 17     Fields:    Translation:Humans
    138. Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclerq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. Urology. 2014 Nov; 84(5):1134-40. PMID: 25443916.
      Citations: 10     Fields:    Translation:Humans
    139. Bhosale PR, Wei W, Ernst RD, Bathala TK, Reading RM, Wood CG, Bedi DG. Intraoperative sonography during open partial nephrectomy for renal cell cancer: does it alter surgical management? AJR Am J Roentgenol. 2014 Oct; 203(4):822-7. PMID: 25247947.
      Citations: 6     Fields:    Translation:Humans
    140. Karmali RJ, Suami H, Wood CG, Karam JA. Lymphatic drainage in renal cell carcinoma: back to the basics. BJU Int. 2014 Dec; 114(6):806-17. PMID: 24841690.
      Citations: 15     Fields:    Translation:Humans
    141. Melkonian SC, Daniel CR, Hildebrandt MA, Tannir NM, Ye Y, Chow WH, Wood CG, Wu X. Joint association of genome-wide association study-identified susceptibility loci and dietary patterns in risk of renal cell carcinoma among non-Hispanic whites. Am J Epidemiol. 2014 Sep 01; 180(5):499-507. PMID: 25053674; PMCID: PMC4143080.
      Citations: 8     Fields:    Translation:Humans
    142. Teegavarapu PS, Rao P, Matrana M, Cauley DH, Wood CG, Tannir NM. Neuroendocrine tumors of the kidney: a single institution experience. Clin Genitourin Cancer. 2014 Dec; 12(6):422-7. PMID: 25088468; PMCID: PMC4253079.
      Citations: 3     Fields:    Translation:Humans
    143. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein J, Tannir NM, Comp?rat E, Couturier J, Molini? V. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res. 2014 Aug 01; 20(15):4129-40. PMID: 24899691; PMCID: PMC4167829.
      Citations: 45     Fields:    Translation:HumansCells
    144. Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM. Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int. 2014 May; 113(5b):E28-33. PMID: 24053608.
      Citations: 7     Fields:    Translation:Humans
    145. Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol. 2014 Jun; 32(3):631-42. PMID: 24744223.
      Citations: 17     Fields:    Translation:Humans
    146. Culp SH, Karam JA, Wood CG. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol. 2014 Jul; 32(5):561-8. PMID: 24709415.
      Citations: 11     Fields:    Translation:Humans
    147. Haddad AQ, Wood CG, Abel EJ, Krabbe LM, Darwish OM, Thompson RH, Heckman JE, Merril MM, Gayed BA, Sagalowsky AI, Boorjian SA, Margulis V, Leibovich BC. Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. J Urol. 2014 Oct; 192(4):1050-6. PMID: 24704115.
      Citations: 23     Fields:    Translation:HumansCells
    148. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9. PMID: 24633966; PMCID: PMC4440575.
      Citations: 54     Fields:    Translation:Humans
    149. Krabbe LM, Bagrodia A, Margulis V, Wood CG. Surgical management of renal cell carcinoma. Semin Intervent Radiol. 2014 Mar; 31(1):27-32. PMID: 24596437; PMCID: PMC3930656.
      Citations: 20     
    150. Abel EJ, Carrasco A, Karam J, Tamboli P, Delacroix S, Vaporciyan AA, Wood CG. Positive vascular wall margins have minimal impact on cancer outcomes in patients with non-metastatic renal cell carcinoma (RCC) with tumour thrombus. BJU Int. 2014 Nov; 114(5):667-73. PMID: 24128265.
      Citations: 7     Fields:    Translation:Humans
    151. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42. PMID: 24518767; PMCID: PMC4502598.
      Citations: 3     Fields:    Translation:Humans
    152. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014 Nov; 66(5):874-80. PMID: 24560330; PMCID: PMC4396847.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    153. Kim DY, Wood CG, Karam JA. Treating the two extremes in renal cell carcinoma: management of small renal masses and cytoreductive nephrectomy in metastatic disease. Am Soc Clin Oncol Educ Book. 2014; e214-21. PMID: 24857105.
      Citations: 3     Fields:    Translation:Humans
    154. Lee DJ, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, Shariat SF, Robinson BD, Margulis V, Xylinas E. Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol. 2014 Aug; 66(2):379-85. PMID: 24388440.
      Citations: 12     Fields:    Translation:Humans
    155. Ngo TC, Wood CG, Karam JA. Biomarkers of renal cell carcinoma. Urol Oncol. 2014 Apr; 32(3):243-51. PMID: 24239464.
      Citations: 15     Fields:    Translation:Humans
    156. Abel EJ, Thompson RH, Margulis V, Heckman JE, Merril MM, Darwish OM, Krabbe LM, Boorjian SA, Leibovich BC, Wood CG. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur Urol. 2014 Sep; 66(3):584-92. PMID: 24262104.
      Citations: 32     Fields:    Translation:Humans
    157. Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-899. PMID: 24086089; PMCID: PMC4441210.
      Citations: 90     Fields:    Translation:Humans
    158. Su SC, Hu X, Kenney PA, Merrill MM, Babaian KN, Zhang XY, Maity T, Yang SF, Lin X, Wood CG. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6461-72. PMID: 24122794; PMCID: PMC4191899.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    159. Youssef RF, Lotan Y, Sagalowsky AI, Shariat SF, Wood CG, Raman JD, Langner C, Zigeuner R, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy? Int Braz J Urol. 2013 Sep-Oct; 39(5):614-21. PMID: 24267122.
      Citations: 4     Fields:    Translation:Humans
    160. Laguna MP. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710. PMID: 24120769.
      Citations:    Fields:    Translation:Humans
    161. Malouf GG, Monzon FA, Escudier B, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM, Couturier J, Molini? V, Camparo P. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res. 2013 Sep 01; 19(17):4673-84. PMID: 23817689; PMCID: PMC3882157.
      Citations: 29     Fields:    Translation:HumansCells
    162. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9. PMID: 23792563; PMCID: PMC3771322.
      Citations: 1409     Fields:    Translation:HumansCells
    163. Faria EF, Caputo PA, Wood CG, Karam JA, Matin SF, Nogueras-Gonz?lez GM. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol. 2014 Feb; 32(1):265-71. PMID: 23783881; PMCID: PMC3874425.
      Citations: 8     Fields:    Translation:Humans
    164. Ahrar K, Ahrar JU, Javadi S, Pan L, Wood CG, Matin SF, Stafford RJ, Milton DR. Real-time magnetic resonance imaging-guided cryoablation of small renal tumors at 1.5 T. Invest Radiol. 2013 Jun; 48(6):437-44. PMID: 23511191; PMCID: PMC3899798.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    165. McKiernan J, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol. 2013 Aug; 190(2):386-8. PMID: 23702308.
      Citations:    Fields:    Translation:Humans
    166. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int. 2013 Jun; 111(7):1068-74. PMID: 23551693; PMCID: PMC3651805.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    167. Karam JA, Wood CG. Words of wisdom: re: prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Eur Urol. 2013 Apr; 63(4):769. PMID: 23438394.
      Citations:    Fields:    
    168. Bagrodia A, Kuehhas FE, Gayed BA, Wood CG, Raman JD, Kapur P, Derweesh IH, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V. Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. Urology. 2013 May; 81(5):972-7. PMID: 23523292.
      Citations: 17     Fields:    Translation:Humans
    169. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005. PMID: 23510233; PMCID: PMC3637414.
      Citations: 5     Fields:    Translation:Humans
    170. Abel EJ, Wood CG, Eickstaedt N, Fang JE, Kenney P, Bagrodia A, Youssef RF, Sagalowsky AI, Margulis V. Preoperative pulmonary embolism does not predict poor postoperative outcomes in patients with renal cell carcinoma and venous thrombus. J Urol. 2013 Aug; 190(2):452-7. PMID: 23434945.
      Citations: 6     Fields:    Translation:Humans
    171. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7. PMID: 23419322; PMCID: PMC3866912.
      Citations: 21     Fields:    Translation:Humans
    172. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst. 2013 Mar 20; 105(6):424-32. PMID: 23378641; PMCID: PMC3601952.
      Citations: 12     Fields:    Translation:HumansCells
    173. Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. 2013 May; 63(5):947-52. PMID: 23273681; PMCID: PMC4378834.
      Citations: 26     Fields:    Translation:Humans
    174. Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, Shariat SF, French National Database on Upper Tract Tumors, Upper Tract Urothelial Carcinoma Collaboration, Roupr?t M, Rozet F. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol. 2013 May; 189(5):1662-9. PMID: 23103802.
      Citations: 56     Fields:    Translation:Humans
    175. Adibi M, Youssef R, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol. 2012 Dec; 19(12):1060-6. PMID: 22882743.
      Citations: 16     Fields:    Translation:Humans
    176. Figlin R, Sternberg C, Wood CG. Novel agents and approaches for advanced renal cell carcinoma. J Urol. 2012 Sep; 188(3):707-15. PMID: 22818130.
      Citations: 44     Fields:    Translation:Humans
    177. Kenney PA, Wood CG. Words of wisdom. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Eur Urol. 2012 Jul; 62(1):182-3. PMID: 22640859.
      Citations: 2     Fields:    
    178. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9. PMID: 22771265; PMCID: PMC3882163.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    179. Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF, Upper Tract Urothelial Carcinoma Collaboration. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol. 2013 Jun; 63(6):1082-90. PMID: 22743166; PMCID: PMC3969987.
      Citations: 28     Fields:    Translation:Humans
    180. Chuang HH, Deniz F, Sircar K, Jimenez C, Rubin De Celis C, Wood CG, Habra MA. [?8F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case. J Clin Oncol. 2012 Sep 10; 30(26):e246-9. PMID: 22649135; PMCID: PMC3434990.
      Citations: 1     Fields:    Translation:Humans
    181. Kenney PA, Wood CG. Integration of surgery and systemic therapy for renal cell carcinoma. Urol Clin North Am. 2012 May; 39(2):211-31, vii. PMID: 22487764.
      Citations: 12     Fields:    Translation:Humans
    182. Wei H, Ke HL, Lin J, Shete S, Wood CG, Hildebrandt MA. MicroRNA target site polymorphisms in the VHL-HIF1a pathway predict renal cell carcinoma risk. Mol Carcinog. 2014 Jan; 53(1):1-7. PMID: 22517515; PMCID: PMC3424388.
      Citations: 11     Fields:    Translation:HumansCells
    183. Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM, Wood CG. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int. 2012 Dec; 110(11):1742-6. PMID: 22503066.
      Citations: 16     Fields:    Translation:Humans
    184. Richey SL, Rao P, Wood CG, Patel S, Tannir NM. Metastatic extraosseous Ewing's sarcoma (EES)/primitive neuroectodermal tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy. Clin Genitourin Cancer. 2012 Sep; 10(3):210-2. PMID: 22503609; PMCID: PMC4121061.
      Citations: 4     Fields:    Translation:Humans
    185. Karam JA, Wood CG. The effects of temporary ischemia in partial nephrectomy on renal functional outcomes: how can effects best be estimated, and can they be mitigated? Eur Urol. 2012 Jul; 62(1):136-8; discussion 138-9. PMID: 22410575.
      Citations:    Fields:    Translation:Humans
    186. Navai N, Wood CG. Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol. 2012 Mar-Apr; 30(2):220-4. PMID: 22385993.
      Citations: 13     Fields:    Translation:HumansAnimalsPHPublic Health
    187. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012 Jul; 62(1):100-14. PMID: 22381168.
      Citations: 124     Fields:    Translation:Humans
    188. Karam JA, Wood CG. Management of small renal masses: watch, cut, freeze, or fry? Eur Urol. 2012 May; 61(5):905-6; discussion 906-7. PMID: 22310973.
      Citations: 2     Fields:    Translation:Humans
    189. Shariat SF, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman JD, Remzi M, Koppie TM, Bensalah K, Guo CC, Mikami S, Sircar K, Ng CK, Haitel A, Kabbani W, Chun FK, Wood CG, Scherr DS, Karakiewicz PI, Langner C. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. Eur Urol. 2012 Aug; 62(2):224-31. PMID: 22285763.
      Citations: 10     Fields:    Translation:Humans
    190. Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V, Mart?nez-Salamanca JI. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012 Apr; 61(4):818-25. PMID: 22284969.
      Citations: 66     Fields:    Translation:Humans
    191. Tobert CM, Uzzo RG, Wood CG, Lane BR. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology. Urol Oncol. 2013 Oct; 31(7):1316-20. PMID: 22264501.
      Citations: 7     Fields:    Translation:Humans
    192. Hildebrandt MA, Tan W, Tamboli P, Huang M, Ye Y, Lin J, Lee JS, Wood CG, Wu X. Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients. Carcinogenesis. 2012 Apr; 33(4):799-803. PMID: 22266464; PMCID: PMC3324439.
      Citations: 13     Fields:    Translation:Humans
    193. Parker PA, Swartz R, Fellman B, Urbauer D, Li Y, Pisters LL, Rosser CJ, Wood CG, Matin SF. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. J Urol. 2012 Mar; 187(3):822-6. PMID: 22245327; PMCID: PMC3866893.
      Citations: 14     Fields:    Translation:Humans
    194. Delacroix SE, Chapin BF, Wood CG. The role of lymph node dissection in renal cell carcinoma. Urol Clin North Am. 2011 Nov; 38(4):419-28, vi. PMID: 22045173.
      Citations: 3     Fields:    Translation:Humans
    195. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhortchouk E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Jinga V, Bencko V, Slamova A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Overvad K, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ, Clavel-Chapelon F, Quir?s JR, Sanchez MJ, Ljungberg B, Tj?nneland A. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet. 2012 Jan 15; 21(2):456-62. PMID: 22010048; PMCID: PMC3276284.
      Citations: 53     Fields:    Translation:HumansCells
    196. Tan W, Hildebrandt MA, Pu X, Huang M, Lin J, Matin SF, Tamboli P, Wood CG, Wu X. Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J Urol. 2011 Nov; 186(5):2071-7. PMID: 21944129; PMCID: PMC3348612.
      Citations: 17     Fields:    Translation:HumansCells
    197. Fischer CP, Wood CG, Shen J, Batiller J, Hart JC, Patel B, Albala DM. A randomized trial of aprotinin-free fibrin sealant versus absorbable hemostat. Clin Appl Thromb Hemost. 2011 Nov-Dec; 17(6):572-7. PMID: 21873356.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    198. Delacroix SE, Chapin BF, Chen JJ, Nogueras-Gonzalez GM, Tamboli P, Matin SF, Wood CG. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol. 2011 Oct; 186(4):1236-41. PMID: 21849197.
      Citations: 16     Fields:    Translation:Humans
    199. Karam JA, Wood CG. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am. 2011 Aug; 25(4):753-64. PMID: 21763966.
      Citations: 6     Fields:    Translation:Humans
    200. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011 Dec; 60(6):1273-9. PMID: 21784574; PMCID: PMC4378714.
      Citations: 30     Fields:    Translation:Humans
    201. Margulis V, Master VA, Cost NG, Leibovich BC, Joniau S, Kuczyk M, Mulders PF, Kirkali Z, Wirth MP, Hirao Y, Rawal S, Chong TW, Wood CG. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. Eur Urol. 2011 Oct; 60(4):673-83. PMID: 21752533.
      Citations: 8     Fields:    Translation:Humans
    202. Youssef RF, Shariat SF, Lotan Y, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F, Bolenz C, Margulis V. Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy. Urol Oncol. 2013 Jul; 31(5):676-81. PMID: 21704538.
      Citations:    Fields:    Translation:Humans
    203. Chapin BF, Delacroix SE, Wood CG. Renal cell carcinoma: what the surgeon and treating physician need to know. AJR Am J Roentgenol. 2011 Jun; 196(6):1255-62. PMID: 21606286.
      Citations: 2     Fields:    Translation:Humans
    204. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71. PMID: 21621907; PMCID: PMC4378825.
      Citations: 29     Fields:    Translation:Humans
    205. Chapin BF, Delacroix SE, Wood CG. The role of lymph node dissection in renal cell carcinoma. Int J Clin Oncol. 2011 Jun; 16(3):186-94. PMID: 21523561.
      Citations:    Fields:    Translation:Humans
    206. Matsumoto K, Novara G, Gupta A, Margulis V, Walton TJ, Roscigno M, Ng C, Kikuchi E, Zigeuner R, Kassouf W, Fritsche HM, Ficarra V, Martignoni G, Tritschler S, Rodriguez JC, Seitz C, Weizer A, Remzi M, Raman JD, Bolenz C, Bensalah K, Koppie TM, Karakiewicz PI, Wood CG, Montorsi F, Iwamura M, Shariat SF. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int. 2011 Oct; 108(8 Pt 2):E304-9. PMID: 21507184.
      Citations: 17     Fields:    Translation:Humans
    207. Chapin BF, Wood CG. The RENAL nephrometry nomogram: statistically significant, but is it clinically relevant? Eur Urol. 2011 Aug; 60(2):249-51; discussion 251-2. PMID: 21514040.
      Citations: 5     Fields:    Translation:Humans
    208. Gurbuz C, Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. J Endourol. 2011 May; 25(5):775-9. PMID: 21388245.
      Citations: 7     Fields:    Translation:Humans
    209. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8. PMID: 21367518.
      Citations: 66     Fields:    Translation:Humans
    210. Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Kabbani W, Langner C, Guo CC, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int. 2011 Oct; 108(8):1286-91. PMID: 21332905.
      Citations: 20     Fields:    Translation:Humans
    211. Karam JA, Wood CG. The dark side of targeted therapy. Eur Urol. 2011 Apr; 59(4):541-2. PMID: 21295398.
      Citations: 1     Fields:    Translation:Humans
    212. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44. PMID: 21167518; PMCID: PMC4668716.
      Citations: 41     Fields:    Translation:Humans
    213. Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Montorsi F, Bolenz C, Margulis V. Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. Urology. 2011 Apr; 77(4):861-6. PMID: 21167566.
      Citations: 11     Fields:    Translation:Humans
    214. Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol. 2011 Apr; 59(4):619-28. PMID: 21167632.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    215. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeney LA, Gaborieau V, Jacobs KB, Chow WH, Zaridze D, Matveev V, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Fabianova E, Bucur A, Bencko V, Foretova L, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Overvad K, Romieu I, Riboli E, Mukeria A, Shangina O, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Weinstein SJ, Virtamo J, Vatten L, Hveem K, Tell GS, Stoltenberg C, Kumar R, Koppova K, Cussenot O, Benhamou S, Oosterwijk E, Vermeulen SH, Aben KK, van der Marel SL, Ye Y, Wood CG, Pu X, Mazur AM, Boulygina ES, Chekanov NN, Foglio M, Lechner D, Gut I, Heath S, Hutchinson A, Thomas G, Wang Z, Yeager M, Fraumeni JF, Skryabin KG, McKay JD, Rothman N, Chanock SJ, Lathrop M, Brennan P, Rudnai P, Clavel-Chapelon F, Quir?s JR, Sanchez MJ, Ljungberg B, Tj?nneland A, Nj?lstad I, Blanche H. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet. 2011 Jan; 43(1):60-5. PMID: 21131975; PMCID: PMC3049257.
      Citations: 133     Fields:    Translation:HumansCells
    216. Abel EJ, Culp SH, Meissner M, Matin SF, Tamboli P, Wood CG. Identifying the risk of disease progression after surgery for localized renal cell carcinoma. BJU Int. 2010 Nov; 106(9):1277-83. PMID: 20394619.
      Citations: 10     Fields:    Translation:Humans
    217. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan; 59(1):10-5. PMID: 20952123; PMCID: PMC4378833.
      Citations: 35     Fields:    Translation:Humans
    218. Sundi D, Svatek RS, Margulis V, Wood CG, Matin SF, Dinney CP, Kamat AM. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol. 2012 May-Jun; 30(3):266-72. PMID: 20869888; PMCID: PMC3034106.
      Citations: 17     Fields:    Translation:Humans
    219. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7. PMID: 20846689; PMCID: PMC4777338.
      Citations: 2     Fields:    Translation:Humans
    220. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010 Nov; 184(5):1877-81. PMID: 20850148; PMCID: PMC4809737.
      Citations: 21     Fields:    Translation:Humans
    221. Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T, van Poppel H, Wood CG. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010 Dec; 58(6):819-28. PMID: 20828919.
      Citations: 29     Fields:    Translation:Humans
    222. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis. 2010 Oct; 31(10):1805-12. PMID: 20732906; PMCID: PMC2981457.
      Citations: 61     Fields:    Translation:Humans
    223. Myers RP, Seki N, Gotoh M, Chai TC, Kaplan SA, Inoue K, Trachtenberg J, Kikuchi E, Nishiyama H, Chang SS, Lee C, Muto S, Ito K, Andriole GL, Eto M, Sumitomo M, Kamba T, Wood CG, Margulis V, Naito S, Egawa S. Fifth joint meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association. Int J Urol. 2010 Aug; 17(8):743-52. PMID: 20649831.
      Citations:    Fields:    Translation:Humans
    224. Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010 Jul 15; 116(14):3378-88. PMID: 20564061.
      Citations: 66     Fields:    Translation:Humans
    225. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010 Jul 01; 116(13):3127-34. PMID: 20564621.
      Citations: 59     Fields:    Translation:Humans
    226. Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Shariat SF, Upper Tract Urothelial Carcinoma Collaborative Group. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol. 2010 Aug; 184(2):453-8. PMID: 20620397.
      Citations: 66     Fields:    Translation:Humans
    227. Childs MA, Wood CG, Spiess PE, Debiane LG, Hernandez M, Matin SF, Millikan RE, Siefker-Radtkie A, Scott SM, Pisters LL. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. Can J Urol. 2010 Jun; 17(3):5184-9. PMID: 20566011.
      Citations: 4     Fields:    Translation:Humans
    228. Wheat JC, Weizer AZ, Wolf JS, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Karakiewizc P, Capitanio U, Bensalah K, Patard JJ, Shariat SF, Fern?ndez M. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 2012 May-Jun; 30(3):252-8. PMID: 20451416.
      Citations: 23     Fields:    Translation:Humans
    229. Wood CG. Editorial comment. J Urol. 2010 Apr; 183(4):1315-6; discussion 1316. PMID: 20171660.
      Citations:    Fields:    Translation:Humans
    230. Tseng-Rogenski S, Gee J, Ignatoski KW, Kunju LP, Bucheit A, Kintner HJ, Morris D, Tallman C, Evron J, Wood CG, Grossman HB, Lee CT, Liebert M. Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol. 2010 Mar; 176(3):1462-8. PMID: 20093479; PMCID: PMC2832165.
      Citations: 33     Fields:    Translation:HumansCells
    231. Karam JA, Wood CG. Editorial comment. J Urol. 2010 Mar; 183(3):870; discussion 870. PMID: 20083268.
      Citations:    Fields:    Translation:Humans
    232. Raman JD, Shariat SF, Karakiewicz PI, Lotan Y, Sagalowsky AI, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, Scherr DS, Remzi M, Waldert M, Wood CG, Margulis V, Upper-Tract Urothelial Carcinoma Collaborative Group. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol. 2011 Nov-Dec; 29(6):716-23. PMID: 20056458.
      Citations: 22     Fields:    Translation:Humans
    233. Chan AA, Wood CG, Caicedo J, Munsell MF, Matin SF. Predictors of unilateral renal function after open and laparoscopic partial nephrectomy. Urology. 2010 Feb; 75(2):295-302. PMID: 19963245.
      Citations: 10     Fields:    Translation:Humans
    234. Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Wood CG, Montorsi F, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C, Fern?ndez MI, Str?bel P. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol. 2010 Apr; 57(4):575-81. PMID: 19959276.
      Citations: 54     Fields:    Translation:Humans
    235. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, Wood CG, Gu J, Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009 Nov 15; 125(10):2342-8. PMID: 19521957; PMCID: PMC2768265.
      Citations: 38     Fields:    Translation:HumansCells
    236. Shariat SF, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Raman JD, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat JC, Zigeuner R, Langner C, Wood CG, Margulis V. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int. 2010 Jun; 105(12):1672-7. PMID: 19912201.
      Citations: 28     Fields:    Translation:Humans
    237. Roscigno M, Shariat SF, Freschi M, Margulis V, Karakiewizc P, Suardi N, Remzi M, Zigeuner R, Bolenz C, Kikuchi E, Weizer A, Bensalah K, Sagalowsky A, Koppie TM, Raman J, Kabbani W, Langner C, Wheat J, Guo CC, Kassouf W, Haitel A, Wood CG, Montorsi F, Fern?ndez M, Str?bel P. Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology. 2009 Nov; 74(5):1070-4. PMID: 19883824.
      Citations: 21     Fields:    Translation:Humans
    238. Delacroix SE, Wood CG. The role of lymphadenectomy in renal cell carcinoma. Curr Opin Urol. 2009 Sep; 19(5):465-72. PMID: 19571759.
      Citations: 2     Fields:    Translation:Humans
    239. Wood CG, Mulders P. Vitespen: a preclinical and clinical review. Future Oncol. 2009 Aug; 5(6):763-74. PMID: 19663726.
      Citations: 16     Fields:    Translation:HumansAnimals
    240. Chiong E, Wood CG, Margulis V. Role of cytoreductive nephrectomy in renal cell carcinoma. Future Oncol. 2009 Aug; 5(6):859-69. PMID: 19663735.
      Citations: 3     Fields:    Translation:Humans
    241. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81. PMID: 19636008; PMCID: PMC4371138.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    242. Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009 Sep; 182(3):900-6. PMID: 19616245.
      Citations: 55     Fields:    Translation:Humans
    243. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Karakiewcz P, Shariat SF, Str?bel P, Fern?ndez M. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2010 Jun; 57(6):1072-9. PMID: 19619934.
      Citations: 51     Fields:    Translation:Humans
    244. Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Sagalowsky A, Bensalah K, Raman JD, Bolenz C, Kassou W, Koppie TM, Wood CG, Wheat J, Langner C, Ng CK, Capitanio U, Bertini R, Mikami S, Isida M, Montorsi F, Fern?ndez MI, Str?bel P. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol. 2009 Sep; 56(3):512-8. PMID: 19559518.
      Citations: 44     Fields:    Translation:Humans
    245. Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 2009 Jul; 6(7):375-83. PMID: 19528960.
      Citations: 16     Fields:    Translation:Humans
    246. Culp SH, Wood CG. Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo- controlled phase III trial. Eur Urol. 2009 Jun; 55(6):1484-5. PMID: 19650216.
      Citations:    Fields:    
    247. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009 May 15; 115(10 Suppl):2247-51. PMID: 19402064; PMCID: PMC2892290.
      Citations: 9     Fields:    Translation:Humans
    248. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer. 2009 May 15; 115(10 Suppl):2355-60. PMID: 19402066.
      Citations: 22     Fields:    Translation:Humans
    249. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood CG, Sandler CM. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics. 2009 May-Jun; 29(3):741-54; discussion 755-7. PMID: 19448113.
      Citations: 37     Fields:    Translation:Humans
    250. Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Mikami S, Isida M, Michel MS, Montorsi F, Fern?ndez MI. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 2009 Jun; 181(6):2482-9. PMID: 19371878.
      Citations: 52     Fields:    Translation:Humans
    251. Capitanio U, Shariat SF, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F, Wood CG, Margulis V, Karakiewicz PI, Fern?ndez MI, Str?bel P. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol. 2009 Jul; 56(1):1-9. PMID: 19361911.
      Citations: 49     Fields:    Translation:Humans
    252. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009 Aug; 104(4):456-60. PMID: 19338544; PMCID: PMC4464661.
      Citations: 16     Fields:    Translation:Humans
    253. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Upper Tract Urothelial Carcinoma CollaborationThe Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009 Mar 15; 115(6):1224-33. PMID: 19156917.
      Citations: 290     Fields:    Translation:Humans
    254. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer. 2009 Mar 15; 115(6):1310-7. PMID: 19156903.
      Citations: 3     Fields:    Translation:Humans
    255. Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol. 2009 May; 181(5):2044-51. PMID: 19286220.
      Citations: 22     Fields:    Translation:Humans
    256. Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P, Wood CG, Wu X. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):801-7. PMID: 19240244; PMCID: PMC2747496.
      Citations: 38     Fields:    Translation:Humans
    257. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20. PMID: 19244175; PMCID: PMC2734116.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    258. Clague J, Shao L, Lin J, Chang S, Zhu Y, Wang W, Wood CG, Wu X. Sensitivity to NNKOAc is associated with renal cancer risk. Carcinogenesis. 2009 Apr; 30(4):706-10. PMID: 19237609; PMCID: PMC2722144.
      Citations: 13     Fields:    Translation:HumansCells
    259. Culp SH, Wood CG. Should patients undergoing surgery for renal cell carcinoma have a lymph node dissection? Nat Clin Pract Urol. 2009 Mar; 6(3):126-7. PMID: 19204738.
      Citations: 1     Fields:    
    260. Siemens R, Morash C, Lacombe L, Jewett M, Goldenberg L, Chin J, Chetner M, Wood CG, Tanguay S, Aprikian AG, Kassouf W. Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J. 2009 Feb; 3(1):73-6. PMID: 19293984; PMCID: PMC2645874.
      Citations: 29     
    261. Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res. 2009 Jan 01; 15(1):81-90. PMID: 19118035; PMCID: PMC3030253.
      Citations: 31     Fields:    Translation:HumansCells
    262. Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, Shariat SF, Fern?ndez MI. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol. 2009 Feb 01; 27(4):612-8. PMID: 19075275; PMCID: PMC2737380.
      Citations: 83     Fields:    Translation:Humans
    263. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, Lin J, Habuchi T, Wu X. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res. 2008 Dec 01; 14(23):7956-62. PMID: 19047128; PMCID: PMC2650498.
      Citations: 115     Fields:    Translation:Humans
    264. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan; 181(1):81-7; discussion 87. PMID: 19012911.
      Citations: 13     Fields:    Translation:Humans
    265. Margulis V, Wood CG. Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU Int. 2009 Jan; 103(2):150-3. PMID: 19007359.
      Citations: 6     Fields:    Translation:Humans
    266. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009 Feb; 73(2):337-41. PMID: 18950837; PMCID: PMC4723280.
      Citations: 8     Fields:    Translation:Humans
    267. Bolenz C, Shariat SF, Margulis V, Lotan Y, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Montorsi F, Bensalah K, Wood CG, Roscigno M, Langner C, Koppie TM, Raman JD, Mikami S, Michel MS, Fern?ndez MI, Str?bel P. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int. 2009 Feb; 103(3):302-6. PMID: 18990164.
      Citations: 30     Fields:    Translation:Humans
    268. Remzi M, Haitel A, Margulis V, Karakiewicz P, Karakiewizc P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Koppie TM, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, Shariat SF, Fern?ndez M, Str?bel P. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009 Feb; 103(3):307-11. PMID: 18990163.
      Citations: 48     Fields:    Translation:Humans
    269. Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Karakiewizc P, Bensalah K, Schultz M, Bernier P, Fern?ndez MI. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology. 2009 Jan; 73(1):142-6. PMID: 18845322.
      Citations: 18     Fields:    Translation:Humans
    270. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol. 2008 Oct; 191(4):1220-32. PMID: 18806169.
      Citations: 58     Fields:    Translation:HumansPHPublic Health
    271. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res. 2008 Oct 01; 14(19):6171-80. PMID: 18809969.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    272. Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, Wood CG. Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway. Clin Cancer Res. 2008 Sep 15; 14(18):5722-30. PMID: 18794080; PMCID: PMC2844539.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    273. Margulis V, Wood CG. Is patient performance status always an accurate surrogate for predicting tumor biology in patients with metastatic renal cancer? Cancer. 2008 Sep 15; 113(6):1282-3. PMID: 18661508.
      Citations:    Fields:    Translation:Humans
    274. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol. 2009 May; 55(5):1135-43. PMID: 18783876; PMCID: PMC10651170.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    275. Margulis V, Lin J, Yang H, Wang W, Wood CG, Wu X. Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway. Cancer Epidemiol Biomarkers Prev. 2008 Sep; 17(9):2366-73. PMID: 18768505; PMCID: PMC2581835.
      Citations: 18     Fields:    Translation:Humans
    276. Margulis V, Matin SF, Wood CG. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol. 2008 Sep; 18(5):474-80. PMID: 18670270.
      Citations: 6     Fields:    Translation:Humans
    277. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer. 2008 Sep; 6(2):122-3. PMID: 18824436.
      Citations: 2     Fields:    Translation:Humans
    278. Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. Cancer J. 2008 Sep-Oct; 14(5):308-14. PMID: 18836335.
      Citations: 7     Fields:    Translation:Humans
    279. Lin J, Pu X, Wang W, Matin S, Tannir NM, Wood CG, Wu X. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis. 2008 Nov; 29(11):2112-9. PMID: 18711149; PMCID: PMC2722861.
      Citations: 11     Fields:    Translation:HumansCells
    280. Xing J, Chen M, Wood CG, Lin J, Spitz MR, Ma J, Amos CI, Shields PG, Benowitz NL, Gu J, de Andrade M, Swan GE, Wu X. Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst. 2008 Aug 06; 100(15):1104-12. PMID: 18664653; PMCID: PMC2720693.
      Citations: 119     Fields:    Translation:HumansCells
    281. Wood C, Srivastava P, Bukowski R, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B, C-100-12 RCC Study Group, Lacombe L. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008 Jul 12; 372(9633):145-154. PMID: 18602688.
      Citations: 106     Fields:    Translation:HumansCTClinical Trials
    282. Matin SF, Ahrar K, Wood CG, Daniels M, Jonasch E. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int. 2008 Sep; 102(8):940-5. PMID: 18485044.
      Citations: 10     Fields:    Translation:Humans
    283. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul; 180(1):94-8. PMID: 18485389.
      Citations: 41     Fields:    Translation:Humans
    284. Margulis V, Wood CG, Jonasch E, Matin SF. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep. 2008 May; 10(3):253-8. PMID: 18765156.
      Citations: 2     Fields:    Translation:Humans
    285. Zhu Y, Horikawa Y, Yang H, Wood CG, Habuchi T, Wu X. BPDE induced lymphocytic chromosome 3p deletions may predict renal cell carcinoma risk. J Urol. 2008 Jun; 179(6):2416-21. PMID: 18433782; PMCID: PMC2810745.
      Citations: 4     Fields:    Translation:HumansCells
    286. Wood CG. Local recurrence after primary therapy for clinically localized prostate cancer: is radiation or surgery "Better" in the salvage setting? J Surg Oncol. 2008 Apr 01; 97(5):376. PMID: 18360819.
      Citations:    Fields:    Translation:Humans
    287. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer. 2008 Apr 01; 112(7):1480-8. PMID: 18240184.
      Citations: 25     Fields:    Translation:Humans
    288. Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis. 2008 May; 29(5):905-12. PMID: 18299279; PMCID: PMC2902381.
      Citations: 23     Fields:    Translation:HumansCells
    289. Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin. 2008 Mar; 24(3):785-94. PMID: 18241525.
      Citations: 8     Fields:    Translation:HumansAnimalsCTClinical Trials
    290. Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol. 2008 Sep; 54(3):489-92. PMID: 18206292.
      Citations: 2     Fields:    Translation:Humans
    291. Wood CG. Adjuvant approaches to renal cell carcinoma. Clin Adv Hematol Oncol. 2008 Jan; 6(1):19-21. PMID: 18322436.
      Citations: 2     Fields:    Translation:Humans
    292. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007 Dec 15; 110(12):2700-8. PMID: 17948916.
      Citations: 4     Fields:    Translation:Humans
    293. Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int. 2007 Dec; 100(6):1235-9. PMID: 17979923.
      Citations: 17     Fields:    Translation:Humans
    294. Booth J, Matin SF, Ahrar K, Tamboli P, Wood CG. Contemporary strategies for treating nonhereditary synchronous bilateral renal tumors and the impact of minimally invasive, nephron-sparing techniques. Urol Oncol. 2008 Jan-Feb; 26(1):37-42. PMID: 18190828.
      Citations: 4     Fields:    Translation:Humans
    295. Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol. 2007 Nov; 178(5):1878-82. PMID: 17868733.
      Citations: 14     Fields:    Translation:Humans
    296. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 Nov; 178(5):1896-900. PMID: 17868729.
      Citations: 23     Fields:    Translation:Humans
    297. Shao L, Wood CG, Zhang D, Tannir NM, Matin S, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007 Oct; 178(4 Pt 1):1492-6. PMID: 17707063.
      Citations: 44     Fields:    Translation:HumansCells
    298. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007 Aug 15; 13(16):4740-9. PMID: 17699851.
      Citations: 160     Fields:    Translation:HumansAnimalsCells
    299. Lin X, Wood CG, Shao L, Huang M, Yang H, Dinney CP, Wu X. Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer. 2007 Jul 15; 110(2):282-8. PMID: 17549681.
      Citations: 3     Fields:    Translation:Humans
    300. Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Troncoso P, Pettaway CA. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int. 2007 Jul; 100(1):63-9. PMID: 17552954.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    301. Margulis V, Wood CG. Update on staging controversies for locally advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2007 Jul; 7(7):909-14. PMID: 17627450.
      Citations:    Fields:    Translation:Humans
    302. Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer. 2007 Jun 15; 109(12):2439-44. PMID: 17487856.
      Citations: 11     Fields:    Translation:Humans
    303. Margulis V, Tamboli P, Cohen DD, Swanson DA, Wood CG, S?nchez-Ortiz RF. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer. 2007 May 15; 109(10):2025-30. PMID: 17420980.
      Citations: 12     Fields:    Translation:Humans
    304. Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant MM, Spiess PE, Wood CG. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology. 2007 May; 69(5):835-8. PMID: 17482917.
      Citations: 8     Fields:    Translation:Humans
    305. Jacobsohn KM, Ahrar K, Wood CG, Matin SF. Is radiofrequency ablation safe for solitary kidneys? Urology. 2007 May; 69(5):819-23; discussion 823. PMID: 17482911.
      Citations: 9     Fields:    Translation:Humans
    306. Gannon CJ, Zager JS, Chang GJ, Feig BW, Wood CG, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007 Jun; 14(6):1870-7. PMID: 17406945.
      Citations: 18     Fields:    Translation:Humans
    307. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007 Mar; 177(3):855-60; discussion 860-1. PMID: 17296358.
      Citations: 12     Fields:    Translation:Humans
    308. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):697s-702s. PMID: 17255296.
      Citations: 19     Fields:    Translation:Humans
    309. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s. PMID: 17255291.
      Citations: 16     Fields:    Translation:Humans
    310. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006 Dec; 98(6):1176-80. PMID: 17125474.
      Citations: 30     Fields:    Translation:Humans
    311. Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer. 2006 Nov 15; 107(10):2375-83. PMID: 17048248.
      Citations: 14     Fields:    Translation:Humans
    312. Matin SF, Dhanani N, Acosta M, Wood CG. Conventional and hand-assisted laparoscopic radical nephrectomy: Comparative analysis of 271 cases. J Endourol. 2006 Nov; 20(11):891-4. PMID: 17144857.
      Citations: 3     Fields:    Translation:Humans
    313. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol. 2006 Oct; 33(5):576-82. PMID: 17045086.
      Citations: 12     Fields:    Translation:Humans
    314. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol. 2006 Oct; 176(4 Pt 1):1463-7. PMID: 16952661.
      Citations: 27     Fields:    Translation:Humans
    315. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology. 2006 Sep; 68(3):528-32. PMID: 16979706.
      Citations: 13     Fields:    Translation:Humans
    316. Wood CG. Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol. 2006 Sep 15; 94(4):264-5. PMID: 16941531.
      Citations: 2     Fields:    Translation:Humans
    317. Howard GE, Wood CG. Staging refinements in renal cell carcinoma. Curr Opin Urol. 2006 Sep; 16(5):317-20. PMID: 16905974.
      Citations: 2     Fields:    Translation:Humans
    318. Canfield SE, Kamat AM, Detry M, Swanson DA, Wood CG, S?nchez-Ortiz RF. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol. 2006 Mar; 175(3 Pt 1):864-9. PMID: 16469567.
      Citations: 21     Fields:    Translation:Humans
    319. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 2006 Feb 15; 66(4):2328-37. PMID: 16489038.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    320. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15; 65(18):8406-13. PMID: 16166319.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    321. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702. PMID: 16030104.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    322. Cohen DD, Matin SF, Steinberg JR, Zagone R, Wood CG. Evaluation of the intact specimen after laparoscopic radical nephrectomy for clinically localized renal cell carcinoma identifies a subset of patients at increased risk for recurrence. J Urol. 2005 May; 173(5):1487-90; discussion 1490-1. PMID: 15821465.
      Citations: 3     Fields:    Translation:Humans
    323. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol. 2005 May; 16(5):679-88. PMID: 15872323.
      Citations: 20     Fields:    Translation:Humans
    324. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ, Guill? F. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005 Apr 20; 23(12):2763-71. PMID: 15837991.
      Citations: 217     Fields:    Translation:Humans
    325. Wyatt RB, Wood CG, Ramirez E, Logothetis C, Pettaway CA, S?nchez-Ortiz RF. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc. 2004 Dec; 96(12):1587-93. PMID: 15622688; PMCID: PMC2568655.
      Citations: 6     Fields:    Translation:Humans
    326. Madsen LT, Bermejo CE, Wen S, Shen Y, Swanson DA, Wood CG, S?nchez-Ortiz RF. A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer. 2004 Nov 15; 101(10):2195-201. PMID: 15470708.
      Citations: 26     Fields:    Translation:Humans
    327. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004 Aug 15; 22(16):3316-22. PMID: 15310775.
      Citations: 101     Fields:    Translation:Humans
    328. Rosser CJ, Madsen LT, Swanson DA, Wood CG, S?nchez-Ortiz RF. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol. 2004 Jun; 171(6 Pt 1):2160-5. PMID: 15126777.
      Citations: 25     Fields:    Translation:Humans
    329. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2587-93. PMID: 15102659.
      Citations: 14     Fields:    Translation:HumansCells
    330. Arap MA, Lahdenranta J, Hajitou A, Marini FC, Wood CG, Wright KC, Fueyo J, Arap W, Pasqualini R. Model of unidirectional transluminal gene transfer. Mol Ther. 2004 Feb; 9(2):305-10. PMID: 14759814.
      Citations: 2     Fields:    Translation:HumansAnimals
    331. Madsen LT, Swanson DA, Canfield SE, Wood CG, S?nchez-Ortiz R. Closed suction or penrose drainage after partial nephrectomy: does it matter? J Urol. 2004 Jan; 171(1):244-6. PMID: 14665885.
      Citations: 5     Fields:    Translation:Humans
    332. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol. 2003 Dec; 170(6 Pt 1):2221-4. PMID: 14634383.
      Citations: 17     Fields:    Translation:Humans
    333. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P, Wood CG. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene. 2003 Sep 11; 22(39):8053-62. PMID: 12970754.
      Citations: 37     Fields:    Translation:HumansCells
    334. Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol. 2003 Sep-Oct; 21(5):327-33. PMID: 14670538.
      Citations: 21     Fields:    Translation:Humans
    335. Wood CG. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am. 2003 Aug; 30(3):581-8. PMID: 12953756.
      Citations: 7     Fields:    Translation:Humans
    336. Tannir N, Ahrar K, Wood CG, S?nchez-Ortiz RF. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol. 2003 Jul; 170(1):178-9. PMID: 12796677.
      Citations: 38     Fields:    Translation:Humans
    337. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol. 2003 Jun; 169(6):2113-7. PMID: 12771730.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    338. Ardelt PU, Wood CG, Chen L, Mintz PJ, Moya C, Arap MA, Wright KC, Pasqualini R, Arap W. Targeting urothelium: ex vivo assay standardization and selection of internalizing ligands. J Urol. 2003 Apr; 169(4):1535-40. PMID: 12629410.
      Citations: 6     Fields:    Translation:HumansCells
    339. Sexton WJ, Wood CG, Kim R, Pisters LL. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol. 2003 Apr; 169(4):1353-6. PMID: 12629359.
      Citations: 9     Fields:    Translation:Humans
    340. Chang DW, Wood CG, Kroll SS, Youssef AA, Babaian RJ. Cavernous nerve reconstruction to preserve erectile function following non-nerve-sparing radical retropubic prostatectomy: a prospective study. Plast Reconstr Surg. 2003 Mar; 111(3):1174-81. PMID: 12621188.
      Citations: 8     Fields:    Translation:Humans
    341. Evans CP, Tunuguntla HS, Saffarian AR, Wood CG. Does retroperitoneal lymphadenectomy for testicular germ cell tumor require a different approach in the presence of horseshoe kidney? J Urol. 2003 Feb; 169(2):503-6. PMID: 12544297.
      Citations: 1     Fields:    Translation:Humans
    342. Madoff DC, Toombs BD, Skolkin MD, Bodurka DC, Modesitt SC, Wood CG, Hicks ME. Endovascular management of ureteral-iliac artery fistulae with Wallgraft endoprostheses. Gynecol Oncol. 2002 Apr; 85(1):212-7. PMID: 11925149.
      Citations: 6     Fields:    Translation:Humans
    343. Spencer TE, Stagg AG, Joyce MM, Jenster G, Wood CG, Bazer FW, Wiley AA, Bartol FF. Discovery and characterization of endometrial epithelial messenger ribonucleic acids using the ovine uterine gland knockout model. Endocrinology. 1999 Sep; 140(9):4070-80. PMID: 10465278.
      Citations: 29     Fields:    Translation:AnimalsCells
    344. Liebert M, Gebhardt D, Wood C, Chen IL, Ellard J, Amancio D, Grossman HB. Urothelial differentiation and bladder cancer. Adv Exp Med Biol. 1999; 462:437-48. PMID: 10599446.
      Citations: 4     Fields:    Translation:Humans
    345. Walls R, Thibault A, Liu L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ, Samid D. The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate. 1996 Sep; 29(3):177-82. PMID: 8827086.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    346. Advances in adjuvant therapies for renal cell carcinoma. Clinical Advances in Hematology and Oncology. 3:1-2.
    347. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma. Modern Pathology. 28:1225-1235.
    348. Interesting cases - A case report. Internet Journal of Advanced Nursing Practice. 4.
    349. Cytoreductive nephrectomy. 109-122.
    350. Editorial Comment. Journal of Urology. 180:93.
    351. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 4.
    352. Combination therapy and function-sparing surgery for muscle-invasive bladder cancer. 183-195.
    353. Surgical management of renal cell carcinoma. Seminars in Interventional Radiology. 31:27-32.
    354. Adjuvant therapy for renal cell carcinoma. 473-495.
    355. Posttraumatic stress and depressive symptoms in renal cell carcinoma. Psycho-Oncology.
    356. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology. 1-10.
    357. Surveillance strategies following curative therapy for localized renal cell carcinoma. 265-273.
    358. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. British Journal of Cancer. 116:77-84.
    359. Editorial Comment. Journal of Urology. 182:458.
    360. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy. Prostate Cancer and Prostatic Diseases. 2.
    361. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    362. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus. BJU International.
    363. Integration of surgery and systemic targeted therapy in the management of patients with metastatic renal cell carcinoma. Japanese Journal of Urology. 101:58.
    364. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC). BJU International. 117:629-635.
    365. Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney. American Journal of Clinical Oncology: Cancer Clinical Trials.
    366. Editorial Comment. Journal of Urology. 180:109.
    367. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney. BJU International.
    368. Adjuvant therapy of RCC. Clinical Advances in Hematology and Oncology. 3:3-4.
    369. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. 33:495.e15-495.e22.
    370. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases. Journal of Urology. 186:454.
    371. Metastases to the kidney. BJU International.
    372. A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. European Urology. 68:980-992.
    373. Erratum. BJU International. 104:574.
    374. DNA methylation signature reveals cell ontogeny of renal cell carcinomas. Clinical Cancer Research. 22:6236-6246.
    375. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN). European Urology.
    376. Tumour angiogenesis as a target for adenoviral mediated antisense gene therapy in human prostate cancer. Prostate Cancer and Prostatic Diseases. 3.
    377. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International.
    378. Authors' response. Radiographics. 29:757.
    379. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology. 1-7.
    380. Sural nerve graft during non-nerve-sparing radical retropubic prostatectomy restores erectile function in patients with locally advanced prostate cancer. Prostate Cancer and Prostatic Diseases. 3.
    381. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma. World Journal of Urology. 1-8.
    382. Reply. Urology. 69:823.
    383. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805). The Lancet.
    384. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clinical Advances in Hematology and Oncology. 14:696-703.
    385. Management and outcomes of patients with renal medullary carcinoma. BJU International.
    386. Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma. Oncotarget. 6:4097-4109.
    387. Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases. Clinical Cancer Research. 21:4048-4054.
    388. Renal tumors. 287-309.
    389. Can high-dose interleukin-2 be replaced with lower-dose, outpatient regimens for metastatic renal cell carcinoma?. Nature Clinical Practice Urology. 2:218-219.
    390. Pubourethral sling simultaneous with radical retropubic prostatectomy for patients at high risk for postprostatectomy incontinence. Prostate Cancer and Prostatic Diseases. 3.
    391. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma. World Journal of Urology. 1-8.
    392. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:166.e21-166.e29.
    393. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Therapeutic Advances in Urology. 8:130-141.
    394. Blood levels of carbonic anhydrase 9 correlate with clear cell renal cell carcinoma activity. Clinical Proteomics. 5:37-45.
    395. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation. Journal of Urology.
    396. Cytoreductive surgery in the era of targeted molecular therapy. Translational Andrology and Urology. 4:301-309.
    397. Editorial Comment. Journal of Urology. 177:68-69.
    398. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations. 33:427.e17-427.e23.
    399. Kidney cancer. 133-142.
    400. Renal angiomyolipoma. 565-586.
    401. Outcome of renal tumors in young adults. Journal of Urology. 175:1243-1244.
    402. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk. Molecular Carcinogenesis. 53:1-7.
    403. Unified approaches to surgery and systemic therapy for renal cell carcinoma. 155-177.
    404. Genomic profiling identifies alterations in TGFβ signaling through loss of TGFβ receptor expression in human renal cell carcinogenesis and progression. Oncogene. 22:8053-8062.
    405. Renal cell carcinoma clinically involving adjacent organs. Journal of Urology. 179:496-497.
    406. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Research. 75:4131-4142.
    407. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene.
    408. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic Renal cell carcinoma. Cancer immunology research. 3:1017-1029.
    409. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology.
    410. Intratumoral heterogeneity. Cancer.
    411. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. European Urology. 66:874-880.
    412. The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. Journal of Urology. 186:452-453.
    413. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations.
    414. Retroperitoneal Lymph Node Dissection in the Management of Testicular Cancer. Operative Techniques in General Surgery. 8:112-116.
    415. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. European Urology.
    416. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European Urology.
    417. Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology. 94:314.e1-314.e7.
    418. G-rich sequence factor 1, a novel marker of prostate cancer virulence identified through mRNA differential display. Prostate Cancer and Prostatic Diseases. 2.
    419. Examination of moderators of expressive writing in patients with renal cell carcinoma. Psycho-Oncology.
    420. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology. 1-9.
    421. Editorial Comment. Journal of Urology. 181:1027.
    422. Genomic DNA hypomethylation and risk of renal cell carcinoma. Clinical Cancer Research. 22:2074-2082.
    423. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. World Journal of Urology. 1-7.
    WOOD's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (711)
    Explore
    _
    Co-Authors (168)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _